SEARCH

SEARCH BY CITATION

References

  • Allahtavakoli M., Shabanzadeh A., Roohbakhsh A. and Pourshanazari A. (2007) Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin. Pharmacol. Toxicol. 101, 309314.
  • Allred C. D. and Kilgore M. W. (2005) Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol. Cell. Endocrinol. 235, 2129.
  • Aoun P., Watson D. G. and Simpkins J. W. (2003) Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur. J. Pharmacol. 472, 6571.
  • Asano M., Nakajima T., Iwasawa K. et al. (1999) Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br. J. Pharmacol. 128, 673683.
  • Awais M., Sato M. and Umezawa Y. (2007) A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells. Biosens. Bioelectron. 22, 25642569.
  • Berger J. and Moller D. E. (2002) The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409435.
  • Berger J. P., Akiyama T. E. and Meinke P. T. (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26, 244251.
  • Biessels G. J., Kamal A., Urban I. J., Spruijt B. M., Erkelens D. W. and Gispen W. H. (1998) Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 800, 125135.
  • Biessels G. J., Staekenborg S., Brunner E., Brayne C. and Scheltens P. (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5, 6474.
  • Brewer L. D., Thibault O., Staton J., Thibault V., Rogers J. T., Garcia-Ramos G., Kraner S., Landfield P. W. and Porter N. M. (2007) Increased vulnerability of hippocampal neurons with age in culture: temporal association with increases in NMDA receptor current, NR2A subunit expression and recruitment of L-type calcium channels. Brain Res. 1151, 2031.
  • Brunton L. L., Sazo J. S. and Parker K. L. (2005) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th edn, pp. 1860. McGraw-Hill Professional, New York, NY.
  • Camacho I. E., Serneels L., Spittaels K., Merchiers P., Dominguez D. and De Strooper B. (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24, 1090810917.
  • Cheung K. H., Shineman D., Muller M. et al. (2008) Mechanism of Ca2+ disruption in Alzheimer’s disease by presenilin regulation of InsP(3) receptor channel gating. Neuron 58, 871883.
  • Choi D. W., Koh J. Y. and Peters S. (1988) Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8, 185196.
  • Cimini A., Benedetti E., Cristiano L., Sebastiani P., D’Amico M. A., D’Angelo B. and Di Loreto S. (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130, 325337.
  • Colca J. R., McDonald W. G., Waldon D. J., Leone J. W., Lull J. M., Bannow C. A., Lund E. T. and Mathews W. R. (2004) Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 286, E252E260.
  • Combs C. K., Johnson D. E., Karlo J. C., Cannady S. B. and Landreth G. E. (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20, 558567.
  • Daynes R. A. and Jones D. C. (2002) Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2, 748759.
  • Dello Russo C., Gavrilyuk V., Weinberg G., Almeida A., Bolanos J. P., Palmer J., Pelligrino D., Galea E. and Feinstein D. L. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. 278, 58285836.
  • Deyo R. A., Straube K. T. and Disterhoft J. F. (1989) Nimodipine facilitates associative learning in aging rabbits. Science 243, 809811.
  • Disterhoft J. F., Thompson L. T., Moyer J. R. Jr and Mogul D. J. (1996) Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. Life Sci. 59, 413420.
  • Etcheberrigaray R., Hirashima N., Nee L., Prince J., Govoni S., Racchi M., Tanzi R. E. and Alkon D. L. (1998) Calcium responses in fibroblasts from asymptomatic members of Alzheimer’s disease families. Neurobiol. Dis. 5, 3745.
  • Feige J. N., Gelman L., Tudor C., Engelborghs Y., Wahli W. and Desvergne B. (2005) Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand. J. Biol. Chem. 280, 1788017890.
  • Feinstein D. L. (2003) Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol. Ther. 5, 6773.
  • Feinstein D. L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V. and Dello Russo C. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70, 177188.
  • Forette F., Seux M. L., Staessen J. A. et al. (2002) The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162, 20462052.
  • Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R. A., Martinez G., Inestrosa N. C. and Bronfman M. (2007) Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 282, 3700637015.
  • Gani O. A. and Sylte I. (2008) Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma. Chem. Biol. Drug. Des. 72, 5057.
  • Gant J. C., Sama M. M., Landfield P. W. and Thibault O. (2006) Early and simultaneous emergence of multiple hippocampal biomarkers of aging is mediated by Ca2+-induced Ca2+ release. J. Neurosci. 26, 34823490.
  • Garcia-Bueno B., Madrigal J. L., Lizasoain I., Moro M. A., Lorenzo P. and Leza J. C. (2005) Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol. Psychiatry 57, 885894.
  • Gardoni F., Kamal A., Bellone C., Biessels G. J., Ramakers G. M., Cattabeni F., Gispent W. H. and Di Luca M. (2002) Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats. J. Neurochem. 80, 438447.
  • Gasparini L., Netzer W. J., Greengard P. and Xu H. (2002) Does insulin dysfunction play a role in Alzheimer’s disease? Trends Pharmacol. Sci. 23, 288293.
  • Gemma C., Stellwagen H., Fister M., Coultrap S. J., Mesches M. H., Browning M. D. and Bickford P. C. (2004) Rosiglitazone improves contextual fear conditioning in aged rats. Neuroreport 15, 22552259.
  • Gibson G. E., Zhang H., Toral-Barza L., Szolosi S. and Tofel-Grehl B. (1996) Calcium stores in cultured fibroblasts and their changes with Alzheimer’s disease. Biochim. Biophys. Acta 1316, 7177.
  • Hauner H. (2002) The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. 18(Suppl 2), S10S15.
  • Hemond P. and Jaffe D. B. (2005) Caloric restriction prevents aging-associated changes in spike-mediated Ca2+ accumulation and the slow afterhyperpolarization in hippocampal CA1 pyramidal neurons. Neuroscience 135, 413420.
  • Heneka M. T., Klockgether T. and Feinstein D. L. (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20, 68626867.
  • Heneka M. T., Sastre M., Dumitrescu-Ozimek L. et al. (2005) Acute treatment with the PPAR{gamma} agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice. Brain 128, 14421453.
  • Hirashima N., Etcheberrigaray R., Bergamaschi S., Racchi M., Battaini F., Binetti G., Govoni S. and Alkon D. L. (1996) Calcium responses in human fibroblasts: a diagnostic molecular profile for Alzheimer’s disease. Neurobiol. Aging 17, 549555.
  • Hofmann C., Lorenz K., Braithwaite S. S., Colca J. R., Palazuk B. J., Hotamisligil G. S. and Spiegelman B. M. (1994) Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134, 264270.
  • Hoyer S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115125.
  • Huang T. J., Sayers N. M., Fernyhough P. and Verkhratsky A. (2002) Diabetes-induced alterations in calcium homeostasis in sensory neurones of streptozotocin-diabetic rats are restricted to lumbar ganglia and are prevented by neurotrophin-3. Diabetologia 45, 560570.
  • Huang T. J., Sayers N. M., Verkhratsky A. and Fernyhough P. (2005) Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats. Exp. Neurol. 194, 279283.
  • Hunter R. L., Dragicevic N., Seifert K., Choi D. Y., Liu M., Kim H. C., Cass W. A., Sullivan P. G. and Bing G. (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 100, 13751386.
  • Hunter R. L., Choi D. Y., Ross S. A. and Bing G. (2008) Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci. Lett. 432, 198201.
  • Inestrosa N. C., Godoy J. A., Quintanilla R. A., Koenig C. S. and Bronfman M. (2005) Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 304, 91104.
  • Ito E., Oka K., Etcheberrigaray R., Nelson T. J., McPhie D. L., Tofel-Grehl B., Gibson G. E. and Alkon D. L. (1994) Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl Acad. Sci. USA, 91, 534538.
  • Janson J., Laedtke T., Parisi J. E., O’Brien P., Petersen R. C. and Butler P. C. (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474481.
  • Jiang Q., Heneka M. and Landreth G. E. (2008) The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications. CNS Drugs 22, 114.
  • Kamal A., Artola A., Biessels G. J., Gispen W. H. and Ramakers G. M. (2003) Increased spike broadening and slow afterhyperpolarization in CA1 pyramidal cells of streptozotocin-induced diabetic rats. Neuroscience 118, 577583.
  • Kapadia R., Yi J. H. and Vemuganti R. (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 13, 18131826.
  • Khachaturian A. S., Zandi P. P., Lyketsos C. G. et al. (2006) Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 63, 686692.
  • Kirischuk S. and Verkhratsky A. (1996) [Ca2+]i recordings from neural cells in acutely isolated cerebellar slices employing differential loading of the membrane-permeant form of the calcium indicator fura-2. Pflugers Arch. 431, 977983.
  • Knock G. A., Mishra S. K. and Aaronson P. I. (1999) Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur. J. Pharmacol. 368, 103109.
  • Kowalska M. and Disterhoft J. F. (1994) Relation of nimodipine dose and serum concentration to learning enhancement in aging rabbits. Exp. Neurol. 127, 159166.
  • Kruglikov I., Gryshchenko O., Shutov L., Kostyuk E., Kostyuk P. and Voitenko N. (2004) Diabetes-induced abnormalities in ER calcium mobilization in primary and secondary nociceptive neurons. Pflugers Arch. 448, 395401.
  • Kumar P., Kaundal R. K., More S. and Sharma S. S. (2009) Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson’s disease. Behav. Brain Res. 197, 398403.
  • LaFerla F. M. (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat. Rev. Neurosci. 3, 862872.
  • Lannert H. and Hoyer S. (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 112, 11991208.
  • Launer L. J. (2005) Diabetes and brain aging: epidemiologic evidence. Curr. Diab. Rep. 5, 5963.
  • Lee G., Elwood F., McNally J. et al. (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem. 277, 1964919657.
  • Levy D. I. and Lipton S. A. (1990) Comparison of delayed administration of competitive and uncompetitive antagonists in preventing NMDA receptor-mediated neuronal death. Neurology 40, 852855.
  • Li L. and Holscher C. (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384402.
  • Li H. and Wei Q. (2001) Conformation changes in brain calcineurin in diabetic rats with or without treatment with vanadyl sulfate. IUBMB Life 51, 373376.
  • Lichtor T., Spagnolo A., Glick R. P. and Feinstein D. L. (2008) PPAR-gamma thiazolidinedione agonists and immunotherapy in the treatment of brain tumors. PPAR Res. 2008, 547470.
  • Lipton S. A. (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1, 101110.
  • Lipton S. A. and Rosenberg P. A. (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613622.
  • Luo Y., Yin W., Signore A. P., Zhang F., Hong Z., Wang S., Graham S. H. and Chen J. (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 97, 435448.
  • Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M. and Tanayama S. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47, 2935.
  • Martin G., Schoonjans K., Lefebvre A. M., Staels B. and Auwerx J. (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem. 272, 2821028217.
  • Mattson M. P. and Guo Q. (1997) Cell and molecular neurobiology of presenilins: a role for the endoplasmic reticulum in the pathogenesis of Alzheimer’s disease? J. Neurosci. Res. 50, 505513.
  • Mattson M. P., Wang H. and Michaelis E. K. (1991) Developmental expression, compartmentalization, and possible role in excitotoxicity of a putative NMDA receptor protein in cultured hippocampal neurons. Brain Res. 565, 94108.
  • McNay E. C. (2005) The impact of recurrent hypoglycemia on cognitive function in aging. Neurobiol. Aging 26(Suppl 1), 7679.
  • De La Monte S. M., Tong M., Lester-Coll N., Plater M. Jr and Wands J. R. (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J. Alzheimer’s Dis. 10, 89109.
  • Moyer J. R. Jr, Thompson L. T., Black J. P. and Disterhoft J. F. (1992) Nimodipine increases excitability of rabbit CA1 pyramidal neurons in an age- and concentration-dependent manner. J. Neurophysiol. 68, 21002109.
  • Moyer J. R. Jr, Power J. M., Thompson L. T. and Disterhoft J. F. (2000) Increased excitability of aged rabbit CA1 neurons after trace eyeblink conditioning. J. Neurosci. 20, 54765482.
  • Munshi M., Grande L., Hayes M., Ayres D., Suhl E., Capelson R., Lin S., Milberg W. and Weinger K. (2006) Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 29, 17941799.
  • Murchison D., Zawieja D. C. and Griffith W. H. (2004) Reduced mitochondrial buffering of voltage-gated calcium influx in aged rat basal forebrain neurons. Cell Calcium 36, 6175.
  • Murphy G. G., Shah V., Hell J. W. and Silva A. J. (2006) Investigation of age-related cognitive decline using mice as a model system: neurophysiological correlates. Am. J. Geriatr. Psychiatry 14, 10121021.
  • Nolte R. T., Wisely G. B., Westin S. et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395, 137143.
  • Norris J. D., Paige L. A., Christensen D. J., Chang C. Y., Huacani M. R., Fan D., Hamilton P. T., Fowlkes D. M. and McDonnell D. P. (1999) Peptide antagonists of the human estrogen receptor. Science 285, 744746.
  • Olney J. W. (2002) New insights and new issues in developmental neurotoxicology. Neurotoxicology 23, 659668.
  • Ott A., Stolk R. P., Van Harskamp F., Pols H. A., Hofman A. and Breteler M. M. (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53, 19371942.
  • Paige L. A., Christensen D. J., Gron H. et al. (1999) Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl Acad. Sci. USA, 96, 39994004.
  • Pathan A. R., Viswanad B., Sonkusare S. K. and Ramarao P. (2006) Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 79, 22092216.
  • Pedersen W. A. and Flynn E. R. (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer’s disease. Neurobiol. Dis. 17, 500506.
  • Pedersen W. A., McMillan P. J., Kulstad J. J., Leverenz J. B., Craft S. and Haynatzki G. R. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199, 265273.
  • Porter N. M., Thibault O., Thibault V., Chen K. C. and Landfield P. W. (1997) Calcium channel density and hippocampal cell death with age in long-term culture. J. Neurosci. 17, 56295639.
  • Rangwala S. M. and Lazar M. A. (2002) The dawn of the SPPARMs? Sci. STKE 2002, PE9.
  • Reagan L. P. (2007) Insulin signaling effects on memory and mood. Curr. Opin. Pharmacol. 7, 633637.
  • Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S. and Mobius H. J. (2003) Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348, 13331341.
  • Riggs B. L. and Hartmann L. C. (2003) Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618629.
  • Risner M. E., Saunders A. M., Altman J. F., Ormandy G. C., Craft S., Foley I. M., Zvartau-Hind M. E., Hosford D. A. and Roses A. D. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 6, 246254.
  • Romera C., Hurtado O., Mallolas J. et al. (2007) Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J. Cereb. Blood Flow Metab. 27, 13271338.
  • Ryan C. M., Freed M. I., Rood J. A., Cobitz A. R., Waterhouse B. R. and Strachan M. W. (2006) Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 29, 345351.
  • Schnaider Beeri M., Goldbourt U., Silverman J. M., Noy S., Schmeidler J., Ravona-Springer R., Sverdlick A. and Davidson M. (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63, 19021907.
  • Schoonjans K., Peinado-Onsurbe J., Lefebvre A. M., Heyman R. A., Briggs M., Deeb S., Staels B. and Auwerx J. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15, 53365348.
  • Steen E., Terry B. M., Rivera E. J., Cannon J. L., Neely T. R., Tavares R., Xu X. J., Wands J. R. and De La Monte S. M. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J. Alzheimer’s Dis. 7, 6380.
  • Strum J. C., Shehee R., Virley D. et al. (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimer’s Dis. 11, 4551.
  • Stutzmann G. E., Smith I., Caccamo A., Oddo S., Parker I. and Laferla F. (2007) Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer’s mouse models. Ann. N Y Acad. Sci. 1097, 265277.
  • Sundararajan S., Jiang Q., Heneka M. and Landreth G. (2006) PPARgamma as a therapeutic target in central nervous system diseases. Neurochem. Int. 49, 136144.
  • Thibault O. and Landfield P. W. (1996) Increase in single L-type calcium channels in hippocampal neurons during aging. Science 272, 10171020.
  • Thibault O., Hadley R. and Landfield P. W. (2001) Elevated postsynaptic [Ca2+]i and L-type calcium channel activity in aged hippocampal neurons: relationship to impaired synaptic plasticity. J. Neurosci. 21, 97449756.
  • Thoennes S. R., Tate P. L., Price T. M. and Kilgore M. W. (2000) Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol. Cell. Endocrinol. 160, 6773.
  • Tombaugh G. C., Rowe W. B. and Rose G. M. (2005) The slow afterhyperpolarization in hippocampal CA1 neurons covaries with spatial learning ability in aged Fisher 344 rats. J. Neurosci. 25, 26092616.
  • Trompet S., Westendorp R. G., Kamper A. M. and De Craen A. J. (2008) Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol. Aging 29, 306308.
  • Uryu S., Harada J., Hisamoto M. and Oda T. (2002) Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 924, 229236.
  • Watson G. S. and Craft S. (2003) The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs 17, 2745.
  • Watson G. S., Cholerton B. A., Reger M. A. et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13, 950958.
  • Willson T. M., Cobb J. E., Cowan D. J. et al. (1996) The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665668.
  • Xing B., Xin T., Hunter R. L. and Bing G. (2008) Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J. Neuroinflammation 5, 4.
  • Yaffe K., Blackwell T., Kanaya A. M., Davidowitz N., Barrett-Connor E. and Krueger K. (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63, 658663.
  • Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A. L., Citron M. and Landreth G. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J. Neurosci. 23, 75047509.
  • Zhang F., Lavan B. E. and Gregoire F. M. (2007) Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res. 2007, 32696.
  • Zhao X., Ou Z., Grotta J. C., Waxham N. and Aronowski J. (2006) Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res. 1073–1074, 460469.
  • Zhou M. and Baudry M. (2006) Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J. Neurosci. 26, 29562963.